AngioDynamics vs Delcath Systems
ANGO and DCTH side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANGO and DCTH compare
Delcath Systems is the larger company, worth 1.4 times as much as AngioDynamics ($755M against $522M).
Delcath Systems grew revenue faster over the last twelve months (38.1% versus 8.2% for AngioDynamics).
Delcath Systems keeps more of each dollar of sales as profit, with a net margin of 6.1% compared with −10.1% at AngioDynamics.
Delcath Systems scores higher on the StockData Score (14 against 12 for AngioDynamics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANGO | DCTH |
|---|---|---|
| Size and price | ||
| Market cap | $522M | $755M |
| Share price | $12.42 | $21.77 |
| Change, 1 year | 1.1% | 154% |
| Change, 5 years | −56.5% | 129% |
| Beta (5Y) | 0.34 | 1.10 |
| Employees | 632 | 156 |
| StockData Score | ||
| Total score | 12 | 14 (better) |
| Valuation score | 2 (better) | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 136× |
| P/S | 1.6× (better) | 6.9× |
| P/B | 3.2× (better) | 5.7× |
| EV/EBITDA | – | 114× |
| P/FCF | 362× | 37.6× (better) |
| FCF yield | 0.28% | 2.7% (better) |
| Fair value | $13.24 | $6.16 |
| Margin of safety | 6.2% (better) | −253% |
| Growth | ||
| Revenue growth (TTM) | 8.2% | 38.1% (better) |
| Revenue growth, 5Y average | 1.9% | – |
| Net income growth (TTM) | – | 455% |
| EPS growth (TTM) | – | 1500% |
| Profitability | ||
| Gross margin | 55.7% | 87.6% (better) |
| Operating margin | −11.2% | 5.2% (better) |
| Net margin | −10.1% | 6.1% (better) |
| FCF margin | 0.44% | 18.3% (better) |
| Return on equity | −19.2% | 5.4% (better) |
| Return on invested capital | −21.4% | 15.5% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.40 | 10.87 (better) |
| Altman Z-score | 2.54 | 26.15 (better) |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 1.1% |
| Shareholder yield | 0.00% | 1.1% (better) |
| Ownership | ||
| Held by institutions | 91.0% | 50.2% |
| Held by insiders | 5.8% | 37.4% |
| Insider net buying, 12 months | −$655K | $150K (better) |
| Short interest, % of float | 5.1% | 8.2% |
Go deeper
- ANGO stock overview
- ANGO income statement
- ANGO valuation and score
- DCTH stock overview
- DCTH income statement
- DCTH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.